Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia

International Journal of Neuropsychopharmacology

Volumn 12, Issue 5, 2009, Pages 599-614

  Vigano, Daniela ^a   Guidali, Cinzia ^a   Petrosino, Stefania ^b   Realini, Natalia ^a   Rubino, Tiziana ^a   Di Marzo, Vincenzo ^b   Parolaro, Daniela ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CNR   (Italy)

Author keywords

Chronic phencyclidine; Cognitive deficit; Endocannabinoid system; Rat; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CANNABIS ADDICTION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; MALE; MEMORY DISORDER; MENTAL TEST; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT; RECOGNITION; SCHIZOPHRENIA;

ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; MALE; PHENCYCLIDINE; RATS; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA;

EID: 69749105664     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009371     Document Type: Article

References (106)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research 169, 263-273.
2. Abdul-Monim Z, Neill JC, Reynolds GP (2007). Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. Journal Psychopharmacology 21, 198-205.
3. Amitai N, Semenova S, Markou A (2007). Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193, 521-537.
4. Andreasen NC, Rezai K, Alliger R, Swayze 2nd VW, Flaum M, Kirchner P, Cohen G, O'Leary DS (1992). Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Archives of General Psychiatry 49, 943-958.
5. Auclair N, Otani S, Soubrie P, Crepel F (2000). Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. Journal Neurophysiology 83, 3287-3293.
6. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgänsberger W, Rammes G (2003). Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learning and Memory 10, 116-128.
7. Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P (2007). Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32, 2098-2107.
8. Barker GR, Bird F, Alexander V, Warburton EC (2007). Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. Journal of Neuroscience 27, 2948-2957.
9. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G, Sadile AG, Giuffrida A, Piomelli D (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. Journal Neuroscience 20, 3401-3407.
10. Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, Scatton B, Le Fur G (2007). CB1 receptor-mediated control of the release of endocannabinoids (as assessed by micro dialysis coupled with LC/MS) in the rat hypothalamus. European Journal of Neuroscience 26, 3458-3464.
11. Bevins RA, Besheer J (2006). Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nature Protocol 1, 1306-1311.
12. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical Journal 322, 671-677.
13. Bortolato M, Aru GN, Frau R, Orrù M, Luckey GC, Boi G, Gessa GL (2005). The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 177, 264-271.
14. Breivogel CS, Childers SR, Deadwyler SA,Hampson RE, Vogt LJ, Sim-Selley LJ (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. Journal Neurochemistry 73, 2447-2459.
15. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003). Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275.
16. Corbillé AG, Valjent E, Marsicano G, Ledent C, Lutz B, Hervé D, Girault JA (2007). Role of cannabinoid type 1 receptors in locomotor activity and striatal signalling in response to psychostimulants. Journal Neuroscience 27, 6937-6947.
17. Coulston CM, Perdices M, Tennant CC (2007). The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia Research 96, 169-184.
18. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB,
19. Krystal JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594-608.
20. Degenhardt L, Hall W (2006). Is cannabis use a contributory cause of psychosis? Canadian journal of psychiatry 51, 556-65.
21. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease 2, 5-14.
22. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
23. Deng C, Han M, Huang XF (2007). No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience Bulletin 23, 341-347.
24. Dere E, Huston JP, De Souza Silva MA (2007). The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neuroscience and Biobehavioural Review 31, 673-704.
25. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
26. Di Marzo V, Berrendero F, Bisogno T, González S,Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernández-Ruiz JJ (2000) Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. Journal of Neurochemistry 74, 1627-1635.
27. Di Marzo V, Cristino L (2008). Why endocannabinoids are not all alike. Nature of Neuroscience 11, 124-126.
28. Kunos G (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822-825.
29. Di Marzo V, Petrosino S (2007). Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology 18, 129-140.
30. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 148, 224-230.
31. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005). Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179, 77-84.
32. Egerton A, Reid L, McGregor S, Cochran SM, Morris BJ, Pratt JA (2008). Sub-chronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198, 37-49.
33. Ferrer B, Gorriti MA, Palomino A, Gornemann I, de Diego Y, Bermudez-Silva FJ, Bilbao A, Fernandez-Espejo E, Moratalla R, Navarro M, Rodŕiguez de Fonseca F (2007). Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. European Journal of Pharmacology 559, 180-183.
34. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent sub-chronic administration of the antibiotic drug minocycline. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 336-339.
35. Fujiwara M, Egashira N (2004). New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. Journal of Pharmacological Sciences 96, 362-266.
36. Gerdeman GL, Ronesi J, Lovinger DM (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nature Neuroscience 5, 446-451.
37. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999). Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nature Neuroscience 2, 358-363.
38. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114.
39. González S, Bisogno T, Wenger T, Manzanares J, Milone A, Berrendero F, Di Marzo V, Ramos JA, Fernández-Ruiz JJ (2000). Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochemical and Biophysical Research Communications 270, 260-266.
40. Gorriti MA, Rodríguez de Fonseca F, Navarro M, Palomo T (1999). Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. European Journal of Pharmacology 365, 133-142.
41. Grayson B, Idris NF, Neill JC (2007). Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 184, 31-38.
42. Hall W, Degenhardt L (2006). What are the policy implications of the evidence on cannabis and psychosis? Canadian Journal of Psychiatry 51, 566-574.
43. Haller J, Szirmai M, Varga B, Ledent C, Freund TF (2005). Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behavioural Pharmacology 16, 415-422.
44. Hajós M, Hoffmann WE, Kocsis B (2008). Activation of Cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biological Psychiatry 63, 1075-1083.
45. Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005). Phencyclidine-induced cognitive deficits in mice are improved by subsequent sub-chronic administration of clozapine, but not haloperidol. European Journal of Pharmacology 519, 114-117.
46. Henquet C, Murray R, Linszen D, van Os J (2005). The environment and schizophrenia: the role of cannabis use. Schizophrenia Bulletin 31, 608-612.
47. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences USA 87, 1932-1936.
48. Idris NF, Repeto P, Neill JC, Large CH (2005). Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology 179, 336-348.
49. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychological Medicine. Monograph Supplement 20, 1-97.
50. Jentsch JD, Redmond Jr. D.E., Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997a). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277, 953-955.
51. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997b). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17, 92-99.
52. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, Piomelli D (2005). Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Molecular Pharmacology 68, 1196-1202.
53. Katona I, Urbán GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, Freund TF (2006). Molecular composition of the endocannabinoid system at glutamatergic synapses. Journal of Neuroscience 26, 5628-5637.
54. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioural models. Journal of Pharmacological and Experimental Therapeutics 313, 199-206.
55. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002). Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology 136, 550-557.
56. Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, Leweke FM, Weis S (2007). Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. Journal of Neural Transmission 114, 1055-1063.
57. Krystal JH, D'Souza DC, Madonick S, Petrakis IL (1999). Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 35 (Suppl.), S35-49.
58. Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO (2001). Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. American Journal of Medical Genetics 105, 749-752.
59. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkötter J, Piomelli D (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29-36.
60. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
61. Linszen DH, Dingemans PM, Lenior ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273-279.
62. Long LE, Malone DT, Taylor DA (2006). Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31, 795-803.
63. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, Gasperi V, Prosperetti C, Bernardi G, Finazzi-Agrò A, Cravatt BF, Centonze D (2008). Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nature Neuroscience 11, 152-159.
64. Madsen MV, Peacock L, Werge T, Andersen MB (2006). Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys. Journal Psychopharmacology 20, 622-628.
65. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, et al. (2008). Antagonistic cannabinoid CB(1)/dopamine D(2) receptor interactions in striatal CB(1)/D(2) heteromers. A combined neurochemical and behavioural analysis. Neuropharmacology 54, 815-823.
66. Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq ZU, Saleh BT (2003). Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Current Medical Research and Opinion 19, 298-305.
67. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534.
68. Masserano JM, Karoum F, Wyatt RJ (1999). SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behavioural Pharmacology 10, 429-432.
69. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M (2004). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. Journal of Neuroscience 24, 10707-10715.
70. McGuire P, Howes OD, Stone J, Fusar-Poli P (2008). Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends in Pharmacological Sciences 29, 91-98.
71. McLean SL, Beck JP, Woolley ML, Neill JC (2008). A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behavioural Brain Research 189, 152-158.
72. Misner DL, Sullivan JM (1999). Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Journal of Neuroscience 19, 6795-6805.
73. Moghaddam B (2002). Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biological Psychiatry 51, 775-787.
74. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352.
75. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 17, 2921-2927.
76. Moreira FA, Guimarães FS (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology 512, 199-205.
77. Newell KA, Deng C, Huang XF (2006). Increasedcannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Experimental Brain Research 172, 556-560.
78. Paxinos G, Watson C (2005). The Rat Brain in Stereotaxic Coordinates, 5th edn. Burlington, MA: Academic Press.
79. Poncelet M, Barnouin MC, Brelière JC, Le Fur G, Soubrié P (1999). Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144, 144-150.
80. Potvin S, Kouassi E, Lipp O, Bouchard RH, Roy MA, Demers MF, Gendron A, Astarita G, Piomelli D, Stip E (2008). Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. Journal of Psychopharmacology. Published online: 28 February 2008. doi:10.1177/ 0269881107083816.
81. Pratt JA, Winchester C, Egerton A, Cochran SM, Morris BJ (2008). Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. British Journal of Pharmacology 153 (Suppl. 1), S465-470.
82. Pryor SR (2000). Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Medical Hypotheses 55, 494-501.
83. Przegaliński E, Göthert M, Frankowska M, Filip M (2005). WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. European Journal of Pharmacology 517, 68-73.
84. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001). Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. Journal of Neuroscience 21, 109-116.
85. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proceedings of the National Academy of Sciences USA 99, 8384-8388.
86. Rodefer JS, Murphy ER, Baxter MG (2005). PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. European Journal of Neuroscience 21, 1070-1076.
87. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D (1997). Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Molecular Brain Research 44, 191-197.
88. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D (2008). Role in anxiety behaviour of the endocannabinoid system in the prefrontal cortex. Cerebral Cortex 18, 1292-1301.
89. Rubino T, Viganò D, Costa B, Colleoni M, Parolaro D (2000a). Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. Journal of Neurochemistry 75, 2478-2484.
90. Rubino T, Viganò D, Massi P, Spinello M, Zagato E, Giagnoni G, Parolaro D (2000b). Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39, 1331-1336.
91. Satoh K, Suzuki T, Narita M, Ishikura S, Shibasaki M, Kato T, Takahashi S, Fukuyama H, Ohnishi H, Morita R (1993). Regional cerebral blood flow in catatonic schizophrenia. Psychiatry Research 50, 203-216.
92. Schneider M, Koch M (2005). Deficient social and play behaviour in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30, 944-957.
93. Semple DM, McIntosh AM, Lawrie SM (2005). Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 19, 187-194.
94. Sim LJ, Selley DE, Xiao R, Childers SR (1996). Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. European Journal of Pharmacology 307, 97-105.
95. Sim-Selley LJ, Martin BR (2002). Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl) methyl]pyrrolo [1,2,3-de]-1,4- benzoxazinyl]-(1-naphthalenyl) methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. Journal of Pharmacology and Experimental Therapeutics 303, 36-44.
96. Sjöström PJ, Turrigiano GG, Nelson SB (2003). Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron 39, 641-654.
97. Straiker A, Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. Journal of Physiology 569, 501-517.
98. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Archives of General Psychiatry 49, 522-530.
99. Ujike H, Morita Y (2004). New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of Pharmacological Sciences 96, 376-381.
100. Valenti M, Viganò D, Cascio MG, Rubino T, Steardo L, Parolaro D, Di Marzo V (2004). Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cellular and Molecular Life Science 61, 945-950.
101. Viganò D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, Parolaro D (2003). Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 28, 1160-1167.
102. Viganò D, Valenti M, Cascio MG, Di Marzo V, Parolaro D, Rubino T (2004). Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience 20, 1849-1857.
103. Weinberger DR, Berman KF, Zec RF (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Archives of General Psychiatry 43, 114-124.
104. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992). Negative symptoms and hypofrontality in chronic schizophrenia. Archives of General Psychiatry 49, 959-965.
105. Wu JC, Buchsbaum MS, Bunney WE (1991). Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo 11, 47-48.
106. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro- psychopharmacology & Biological Psychiatry 28, 355-360.